Cardiff Lexington Announces Third Quarter 2025 Financial Results

About this update from Cardiff Lexington Corporation

Cardiff Lexington Announces Third Quarter 2025 Financial Results Cardiff Lexington Announces Third Quarter 2025 Financial Results 125.6% increase in total revenue to $3.1 million compared to 3Q24 437.8% increase in gross profit to $1.9 million compared to 3Q24 209.9% increase in income from continuing operations to $643,000 compared to 3Q24 LEXINGTON, KY / ACCESS Newswire / November 14, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the third quarter ended September 30, 2025. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Rebounding from our one-time $1.7 million charge to revenue reported in the third quarter of 2024, our third 2025 quarter results were highlighted by triple-digit revenue growth and significantly enhanced gross margin when compared to the third quarter of 2024. We also drove improved results on a sequential basis in 2025, demonstrating the steadily increasing demand for our services as patient volume continues to grow. In addition to organic growth, M&A remains a priority for us as we look to further leverage our market positioning, diversify our model and drive growing profitability and long-term value for shareholders." Third Quarter 2025 Financial Results Total revenue increased 125.6% to $3.1 million compared with $1.4 million in the third quarter of 2024. Revenue in the third quarter of 2024 included a one-time change in accounting estimate of the billing realization rate resulting in a charge of $1.7 million. Non-GAAP adjusted revenue, excluding the one-time non-cash adjustment, was $3.0 million for this period. The following third quarter 2024 results include the one-time adjustment to third quarter 2024 revenue. Gross profit increased 437.8% to $1.9 million, or 62.4% of total revenue, compared with $355,000, or 26.2% of total revenue in the third quarter of 2024. Total operating expenses increased to $1.3 million compared with $940,000 in the third quarter of 2024. The increase in operating expenses is related to SG&A expense of $1.2 million, or 40.0% of revenue, in the third quarter of 2025, compared with $937,000, or 69.1% of revenue, in the third quarter of 2024, as well as stock compensation expense of $41,000 in the third quarter of 2025. Income from continuing operations increased 209.9% to $643,000, or 21.0% of total revenue, in the third quarter of 2025, compared with an operating loss of $(585,000), or (43.2%) of total revenue, in the third quarter of 2024. Net loss in the third quarter of 2025 was $(1.1 million) compared with net loss of $(2.0 million) in the third quarter of 2024. Included in net loss for the three months ended September 30, 2025, was interest expense of $(1.8 million) compared with interest expense of $(1.4 million) in the third quarter of 2024. This increase in interest expense is related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit. Non-GAAP adjusted EBITDA, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024, was $663,000, compared with non-GAAP adjusted EBITDA of $1.1 million in the third quarter of 2024. During the three months ended June 30, 2025, as part of the Company's ongoing enhancements to internal controls over financial reporting, a detailed review of its interest expense-related cash flow classification was performed. As a result, the Company restated certain amounts within the condensed consolidated statement of cash flows for the nine months ended September 30, 2024. This was reclassified to correct the presentation of $1,953,667 of non-cash interest accrual adjustments related to the Company's line of credit as of September 30, 2024. These amounts, previously presented within net proceeds from the line of credit in financing activities, are now presented within operating activities. This change in presentation has no impact on the Company's condensed consolidated balance sheets, condensed consolidated statements of operations, or total cash flows for any related period. Year-to-Date Financial Highlights Total revenue increased 70.2% to $8.8 million compared with $5.1 million in the first nine months of 2024. Revenue in the first nine months of 2024 included a one-time adjustment of $2.8 million. Non-GAAP adjusted revenue, excluding the one-time non-cash adjustment, was $8.0 million for this period. The following year-to-date 2024 results include the one-time adjustment to third quarter 2024 revenue. Gross profit increased 126.2% to $5.4 million, or 62.1% of total revenue, compared with $2.4 million, or 46.8% of total revenue in the first nine months of 2024. Total operating expenses increased to $3.6 million compared with $2.9 million in the first nine months of 2024, primarily related to increased SG&A expense of $3.5 million, or 39.9% of revenue, compared with $2.6 million, or 50.9% of revenue, for the nine months ended September 30, 2024. Operating income increased to $1.8 million, or 20.5% of total revenue, compared with operating loss of $(526,000), or (10.2%) of total revenue, in the first nine months of 2024. Net loss in the first nine months of 2025 was $(2.8 million) compared with net loss of $(2.4 million) in the first nine months of 2024. Included in net loss for the nine months ended September 30, 2025, was interest expense of $(4.6 million) compared with interest expense of $(1.8 million) in the first nine months of 2024. This increase in interest expense is primarily related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit. Non-GAAP adjusted EBITDA, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024, was $1.9 million compared with non-GAAP adjusted EBITDA of $1.5 million in the first nine months of 2024. Balance Sheet Cash totaled $232,000 as of September 30, 2025. Total assets increased 15.4% to $27.6 million as of September 30, 2025. Conference Call Cardiff Lexington will hold a conference call and webcast for investors today, November 14, 2025, at 9:00 a.m. Eastern Time. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 223050. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/53160 The conference call and slide deck may also be accessed via the Investor Relations page of the Company's website at https://investor.cardifflexington.com/overview/default.aspx . Please allow extra time prior to the call to visit the site. An online archive of the webcast will be available on the Investor Relations page of the Company's website following the call at https://investor.cardifflexington.com/overview/default.aspx . A replay of the conference call will be available one hour after completion of the call until Friday, November 28, 2025, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53160 to access the replay. ----- About Cardiff Lexington Corporation: Cardiff Lexington Corporation (OTCQB: CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance . All current revenue is derived from Nova Ortho and Spine, LLC , which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations. For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/ FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Use of Non-GAAP Financial Measures Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures. Cardiff Lexington Investor Relations [email protected] (800) 628-2100 ext. 705 or IMS Investor Relations [email protected] (203) 972-9200 CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024 (Unaudited) For the Three Months Ended For the Nine Months Ended September 30, September 30, September 30, September 30, 2025 2024 2025 2024 Total revenue $ 3,058,740 $ 1,355,641 $ 8,763,314 $ 5,149,416 Total cost of sales 1,149,161 1,000,601 3,317,943 2,741,765 Gross profit 1,909,579 355,040 5,445,371 2,407,651 Operating expenses Depreciation expense 762 3,365 4,890 10,096 Loss on disposal of fixed assets 0 0 12,593 0 Stock compensation expense 41,188 0 138,688 300,225 Selling, general and administrative 1,224,350 936,835 3,492,310 2,622,981 Total operating expenses 1,266,300 940,200 3,648,481 2,933,302 Income (loss) from continuing operations 643,279 (585,160 ) 1,796,890 (525,651 ) Other (expense) income: Other expense (20,550 ) (6,767 ) (22,147 ) (4,720 ) Gain on debt refinance, forgiveness and settlement 0 0 0 78,834 Penalties and fees (1,500 ) 0 (1,500 ) (1,330 ) Interest expense (1,765,528 ) (1,386,041 ) (4,594,714 ) (1,803,657 ) Amortization of debt discounts 0 0 0 (24,821 ) Total other expense (1,787,578 ) (1,392,808 ) (4,618,361 ) (1,755,694 ) Net loss before discontinued operations (1,144,299 ) (1,977,968 ) (2,821,471 ) (2,281,345 ) Loss from discontinued operations 0 0 0 (111,312 ) Net loss $ (1,144,299 ) $ (1,977,968 ) $ (2,821,471 ) $ (2,392,657 ) CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2025, AND DECEMBER 31, 2024 (Unaudited) September 30, December 31, 2025 2024 ASSETS Current assets Cash $ 232,033 1,188,185 Accounts receivable-net 20,699,999 15,934,490 Prepaid and other current assets 112,514 89,901 Total current assets 21,044,546 17,212,576 Property and equipment, net 3,715 21,198 Land 540,000 540,000 Goodwill 5,666,608 5,666,608 Right of use - assets 281,514 406,950 Due from related party 4,979 4,979 Other assets 68,154 73,368 Total assets $ 27,609,516 23,925,679 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' (DEFICIT)/EQUITY Current liabilities Accounts payable and accrued expense $ 1,659,791 1,379,760 Accrued expenses - related parties 4,722,691 4,553,057 Accrued interest 567,986 429,200 Right of use - liability 214,002 223,330 Notes - current portion 200,803 312,180 Line of credit 14,727,190 8,645,991 Convertible notes payable, net of debt discounts of $0 and $24,821, respectively 50,000 105,000 Net liabilities of discontinued operations 238,285 238,285 Total current liabilities 22,380,748 15,886,803 Other liabilities Notes payable 139,590 251,725 Operating lease liability - long term 75,727 185,877 Total liabilities 22,596,065 16,324,405 Mezzanine equity Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,006,857 and 921,636 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 3,680,194 3,339,317 Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 427,690 and 397,464 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1,697,687 1,576,788 Total Mezzanine Equity 5,377,881 4,916,105 Stockholders' (deficit)/equity Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 0 and 1,279,867 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 0 5,119,468 Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 0 and 74 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 0 296 Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 175,375 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 0 701,500 Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 3,875 shares issued and outstanding at September 30, 2025 and December 31, 2024 15,500 15,500 Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 10,075,092 and 10,469,092 issued and outstanding at September 30, 2025 and December 31, 2024, respectively 40,300,368 41,876,368 Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at September 30, 2025 and December 31, 2024 1,277,972 1,277,972 Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, $0.001 par value, stated value of $4.00, 1,041,764 and 979,125 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 4,167,056 3,916,500 Common Stock: 300,000,000 shares authorized, $0.001 par value; 19,904,708 and 15,300,475 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 19,905 15,300 Additional paid-in capital 30,388,568 22,711,350 Accumulated deficit (76,533,799 ) (72,949,085 ) Total stockholders' (deficit)/equity (364,430 ) 2,685,169 Total liabilities, mezzanine equity and stockholders' equity $ 27,609,516 23,925,679 CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024 (Unaudited) The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure) For the Three Months Ended For the Nine Months Ended September 30, September 30, 2025 2024 2025 2024 EBITDA (1) Net loss before discontinued operations $ (1,144,299 ) $ (1,977,968 ) $ (2,821,471 ) $ (2,281,345 ) Add: Interest 1,765,528 1,386,041 4,594,714 1,803,657 Taxes 0 0 0 0 Depreciation 762 3,365 4,890 10,096 Amortization 0 0 0 24,821 EBITDA (1) $ 621,991 $ (588,562 ) $ 1,778,133 $ (442,771 ) Adjusted EBITDA (2) EBITDA $ 621,991 $ (588,562 ) $ 1,778,133 $ (442,771 ) Add: Change in estimate for settlement realization rate 0 1,650,474 0 1,650,474 Stock compensation expense for shares issued 41,188 0 138,688 300,225 Adjusted EBITDA (2) $ 663,179 $ 1,061,912 $ 1,916,821 $ 1,507,928 (1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization. (2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges. Adjusted EBITDA excluding other non-recurring costs (3) Adjusted EBITDA $ 663,179 $ 1,061,912 $ 1,916,821 $ 1,507,928 Add: Scaling and restructuring costs for business growth 0 76,110 11,676 180,302 Acquisition related costs 113,436 0 171,515 0 Adjusted EBITDA excluding other non-recurring costs (3) $ 776,615 $ 1,138,022 $ 2,100,012 $ 1,688,230 3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs. CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES RECONCILIATION OF REVENUE FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024 (Unaudited) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2025 2024 2025 2024 GAAP Revenue $ 3,058,740 $ 1,355,641 $ 8,763,314 $ 5,149,416 Adjustments to Claim Settlement Realization Rate - 1,650,474 - 2,849,629 Non-GAAP Adjusted Revenue $ 3,058,740 $ 3,006,115 $ 8,763,314 $ 7,999,045 SOURCE: Cardiff Lexington Corporation View the original press release on ACCESS Newswire https://app.accessnewswire.com/img.ashx?id=1102261 © Copyright 2025 ACCESS Newswire. All Rights Reserved.

View stock analysis, news, and events for Cardiff Lexington Corporation